Translational Development of Novel Ligands for Cardiac and Renal Diseases

The Ottawa Heart Institute is active in the development of novel radiopharmaceutical agents for PET imaging of cardiac diseases. Dr. DaSilva describes several tracer development programs at the OHI, together with their targets and development status, particularly those to Angiotensin II. Enhanced visualization of disease targets can then be used to guide therapy in cardiac and renal events.